Avenue Therapeutics Inc (ATXI)

Nov 14, 2024, 4:05 PM EST - 2 months ago

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Oct 9, 2024, 8:30 AM EDT - 3 months ago

Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit

Sep 3, 2024, 8:30 AM EDT - 4 months ago

Avenue Therapeutics to Participate in Upcoming Investor Conferences

Aug 9, 2024, 4:05 PM EDT - 5 months ago

Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Jun 20, 2024, 8:30 AM EDT - 7 months ago

Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

May 16, 2024, 8:30 AM EDT - 8 months ago

Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

May 15, 2024, 8:30 AM EDT - 8 months ago

Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Apr 29, 2024, 8:00 AM EDT - 9 months ago

Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds

Apr 24, 2024, 7:30 AM EDT - 9 months ago

Avenue Therapeutics Announces Reverse Stock Split

Mar 25, 2024, 8:30 AM EDT - 10 months ago

Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

Mar 18, 2024, 4:05 PM EDT - 10 months ago

Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights

Mar 15, 2024, 8:15 AM EDT - 11 months ago

Avenue Therapeutics Receives Positive Listing Determination from Nasdaq

Mar 11, 2024, 8:00 AM EDT - 11 months ago

Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting

Feb 22, 2024, 8:30 AM EST - 11 months ago

Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy

Jan 11, 2024, 8:00 AM EST - 1 year ago

Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference

Jan 5, 2024, 9:15 AM EST - 1 year ago

Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds

Jan 4, 2024, 8:30 AM EST - 1 year ago

Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol

Jan 2, 2024, 8:30 AM EST - 1 year ago

Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Dec 1, 2023, 8:30 AM EST - 1 year ago

Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting

Nov 13, 2023, 4:05 PM EST - 1 year ago

Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 2, 2023, 3:00 PM EDT - 1 year ago

Avenue Therapeutics Announces Closing of $5.0 Million Public Offering

Oct 31, 2023, 9:15 AM EDT - 1 year ago

Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering

Sep 5, 2023, 8:30 AM EDT - 1 year ago

Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 10, 2023, 4:15 PM EDT - 1 year ago

Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Aug 1, 2023, 8:30 AM EDT - 1 year ago

Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study

Jul 27, 2023, 8:30 AM EDT - 1 year ago

Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Jul 25, 2023, 8:30 AM EDT - 1 year ago

Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol

May 12, 2023, 8:30 AM EDT - 1 year ago

Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Apr 27, 2023, 8:30 AM EDT - 1 year ago

Avenue Therapeutics to Present at Aegis Capital Virtual Conference

Apr 17, 2023, 4:01 PM EDT - 1 year ago

Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol

Mar 30, 2023, 4:01 PM EDT - 1 year ago

Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights

Mar 8, 2023, 4:01 PM EST - 2 years ago

Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates

Mar 2, 2023, 8:00 AM EST - 2 years ago

Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy

Jan 31, 2023, 1:30 PM EST - 2 years ago

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI)

FBIO

Jan 31, 2023, 1:09 PM EST - 2 years ago

Avenue Therapeutics Announces Closing of $3.25 Million Registered Direct and Private Placement

Jan 27, 2023, 11:58 AM EST - 2 years ago

Avenue Therapeutics Announces $3.25 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules

Nov 10, 2022, 4:10 PM EST - 2 years ago

Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Nov 8, 2022, 8:30 AM EST - 2 years ago

Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders

Oct 12, 2022, 10:25 AM EDT - 2 years ago

Aegis Capital Corp. Acted as Sole Bookrunner on a $12 Million Underwritten Public Offering for Avenue Therapeutics, Inc. (NASDAQ:ATXI)

Oct 11, 2022, 2:15 PM EDT - 2 years ago

Avenue Therapeutics Announces Closing of $12 Million Underwritten Public Offering

Oct 7, 2022, 9:21 AM EDT - 2 years ago

What In The World Is Going On With Avenue Therapeutics Stock?

Oct 6, 2022, 11:00 PM EDT - 2 years ago

Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering

Sep 22, 2022, 4:25 PM EDT - 2 years ago

Avenue Therapeutics Announces Reverse Stock Split and Provides Regulatory Update for IV Tramadol Including Receipt of Type A Meeting Minutes from the FDA

Feb 15, 2022, 10:00 PM EST - 3 years ago

Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol

Feb 15, 2022, 7:05 AM EST - 3 years ago

Avenue Therapeutics Stock Trading Halted Today

Dec 15, 2021, 2:15 PM EST - 3 years ago

Aegis Capital Corp. Acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI)

Dec 15, 2021, 12:00 PM EST - 3 years ago

Avenue Therapeutics Announces Closing of Public Offering of Common Stock

Dec 12, 2021, 8:00 PM EST - 3 years ago

Avenue Therapeutics Prices $2.0 Million Underwritten Public Offering of Common Stock

Nov 17, 2021, 9:30 AM EST - 3 years ago

Avenue Therapeutics Announces Exercise and Closing of Underwriter's Over-Allotment Option

Nov 12, 2021, 10:40 AM EST - 3 years ago

Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI)